Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
667.2(c) 670(c) 666.7(c) 667.9(c) 677.4(c) Last
1 431 615 1 910 479 1 512 009 1 330 606 1 404 067 Volume
+1.40% +0.42% -0.49% +0.18% +1.42% Change
More quotes
Estimated financial data (e)
Sales 2021 138 B 21 535 M 21 535 M
Net income 2021 46 476 M 7 278 M 7 278 M
Net cash position 2021 6 424 M 1 006 M 1 006 M
P/E ratio 2021 33,5x
Yield 2021 1,47%
Sales 2022 151 B 23 639 M 23 639 M
Net income 2022 51 083 M 7 999 M 7 999 M
Net cash position 2022 11 983 M 1 876 M 1 876 M
P/E ratio 2022 30,1x
Yield 2022 1,62%
Capitalization 1 550 B 242 B 243 B
EV / Sales 2021 11,2x
EV / Sales 2022 10,2x
Nbr of Employees 45 971
Free-Float 69,8%
More Financials
Company
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of... 
Sector
Pharmaceuticals
Calendar
11/03 | 01:30amEarnings Release
More about the company
Ratings of Novo Nordisk A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about NOVO NORDISK A/S
10/20Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris
RE
10/18NOVO NORDISK A/S : Share repurchase programme - Form 6-K
PU
10/18NOVO NORDISK A/S : – Share repurchase programme
AQ
10/18NOVO NORDISK : Gets a Buy rating from Barclays
MD
10/14NOVO NORDISK : Buy rating from Goldman Sachs
MD
10/12NOVO NORDISK A/S : Share repurchase programme - Form 6-K
PU
10/05NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
10/05Xeris Pharmaceuticals, Inc. completed the acquisition of Strongbridge Biopharma plc fro..
CI
10/04NOVO NORDISK A/S : – Share repurchase programme
AQ
09/28NOVO NORDISK : JP Morgan reiterates its Buy rating
MD
09/27GLOBAL MARKETS LIVE : Intel, Apple, Rolls-Royce, Raytheon, MGM...
09/27NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
09/27BIOCORP : To Develop Add-On Device For Novo Nordisk's Insulin Pen
MT
09/27Biocorp and Novo Nordisk Sign Global Partnership Within Diabetes on Digital Health
CI
09/25NOVO NORDISK A/S : Matheson Advises Novo Nordisk A/S On The Purchase Of Neotope Neuroscien..
AQ
More news
News in other languages on NOVO NORDISK A/S
10/15Investir dans la stabilité
10/07Time to fly (to quality) ?
10/06Time to fly (to quality) ?
10/01L'OMS veut améliorer l'accès aux traitements contre le diabète
09/29MÄRKTE EUROPA/Erholungsbewegung nach massivem Abverkauf
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Stock Trading Strategies
NOVO NORDISK A/S - 09/16
No turn-around in sight
BUY
More Stock Trading Analysis
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 677,40 DKK
Average target price 613,52 DKK
Spread / Average Target -9,43%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S58.77%242 392
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
ELI LILLY AND COMPANY42.84%218 640
MERCK & CO., INC.-0.77%205 472